Ciglitazone

Ciglitazone

SCHEMBL6203612

CC1(COc2ccc(CC3SC(=O)NC3=O)cc2)CCCCC1.O=C1CSC(=O)N1

nearest known ligand 0.84

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.84
CYP3A4 P08684 2/20 0.84
MEN1 O00255 1/20 0.84
ALDH1A1 P00352 1/20 0.84
TP53 P04637 1/20 0.84
CYP1A2 P05177 1/20 0.84
MAPT P10636 1/20 0.84
ALOX15 P16050 1/20 0.84
TSHR P16473 1/20 0.84
KMT2A Q03164 1/20 0.84
HSD17B10 Q99714 1/20 0.84
TDP1 Q9NUW8 1/20 0.84
HRH3 Q9Y5N1 1/20 0.53
FFAR1 O14842 6/20 0.49
PPARA Q07869 3/20 0.49
PPARG P37231 9/20 0.48
PARP1 P09874 1/20 0.46
RXRA P19793 1/20 0.46
MPC2 O95563 2/20 0.45
CYP2C8 P10632 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ciglitazone SCHEMBL38185 0.92 HPGD (1.00) HPGDCYP3A4MEN1ALDH1A1TP53
Ciglitazone SCHEMBL20125576 0.92 HPGD (1.00) HPGDCYP3A4MEN1ALDH1A1TP53
Ciglitazone SCHEMBL20125581 0.92 HPGD (1.00) HPGDCYP3A4MEN1ALDH1A1TP53
Ciglitazone SCHEMBL21582134 0.91 HPGD (0.98) HPGDCYP3A4MEN1ALDH1A1TP53
Ciglitazone SCHEMBL3189397 0.91 HPGD (0.98) HPGDCYP3A4MEN1ALDH1A1TP53
Ciglitazone SCHEMBL8498957 0.87 HPGD (0.89) HPGDCYP3A4MEN1ALDH1A1TP53
SCHEMBL11091437 0.82 CYP3A4 (0.81) HPGDCYP3A4MEN1ALDH1A1TP53
SCHEMBL12521714 0.81 HPGD (0.79) HPGDCYP3A4MEN1ALDH1A1TP53
SCHEMBL11088249 0.81 CYP3A4 (0.79) HPGDCYP3A4MEN1ALDH1A1TP53
SCHEMBL11083961 0.81 CYP3A4 (0.78) HPGDCYP3A4MEN1ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1505948-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2005-02-16 EP disclosed
US-20030220300-A1 Reduction of hair growth GILLETTE COMPANY, THE 2003-11-27 US disclosed
WO-2003096997-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2003-11-27 WO disclosed
EP-0804193-A4 THIAZOLIDINE DERIVATIVES FOR THE TREATMENT OF PSORIASIS KURTZ THEODORE W (US) 2002-03-27 EP disclosed
US-5824694-A Thiazolidine derivatives for the treatment of psoriasis BETHESDA PHARMACEUTICALS, INC. (US) 1998-10-20 US disclosed
EP-0804193-A1 THIAZOLIDINE DERIVATIVES FOR THE TREATMENT OF PSORIASIS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-11-05 EP disclosed
US-5594015-A Thiazolidine derivatives for the treatment of psoriasis REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-01-14 US disclosed
WO-1995035108-A1 THIAZOLIDINE DERIVATIVES FOR THE TREATMENT OF PSORIASIS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1995-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220300-A1 Reduction of hair growth FGF1, FGF2, MKI67 HPGD 432/4885CYP3A4 2914/4885MEN1 4090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.